Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 623 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Cirrhosis Clear all
Completed Phase 1 Interventional

Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis

NCT03416751
View directory record Official record
Conditions
Cirrhosis, Alcohol Abuse
Interventions
Fecal Microbial Transplant, Placebo
Biological · Other
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus

NCT03995212
View directory record Official record
Conditions
Cholestatic Pruritus
Interventions
CR845 1.0 mg, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Coronado, California • Rialto, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Phase 3 Interventional

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

NCT06016842
View directory record Official record
Conditions
Primary Biliary Cholangitis (PBC)
Interventions
Elafibranor, Matched 80 mg placebo
Drug · Other
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
43
States / cities
Tucson, Arizona • Little Rock, Arkansas • Coronado, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

NCT00244751
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
GI262570 0.5 mg, GI262570 1.0 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

Prevention of Recurrent Hepatitis B After Liver Transplantation

NCT00059267
View directory record Official record
Conditions
Hepatitis B, Cirrhosis, Acute Liver Failure, Hepatocellular Carcinoma
Interventions
HBIG, Epivir, Hepsera
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
13 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

NCT01937130
View directory record Official record
Conditions
Acute on Chronic Hepatic Failure, Acute Liver Failure, Liver Cirrhosis, Acute Alcoholic Hepatitis
Interventions
IDN-6556, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2016 · Synced Oct 2, 2026, 4:11 AM EDT
Active, not recruiting Phase 2 Interventional

Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM

NCT06005012
View directory record Official record
Conditions
Fibrosis, Liver, Type 2 Diabetes Mellitus in Obese, Non-Alcoholic Fatty Liver Disease
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

NCT02966795
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis

NCT04867954
View directory record Official record
Conditions
Cirrhosis, Liver, Gastroesophageal Varices, Fontan Procedure
Interventions
Ensure Plus®, Pre-clinical validation contrast enhanced MRI, Clinical validation MRI, Pre-clinical validation contrast enhanced MRI + fasting
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

NCT01264705
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Cancer
Interventions
bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 2, 2026, 4:11 AM EDT
Withdrawn Phase 4 Interventional

Rifaximin Versus Lactulose in Renal Failure

NCT00748904
View directory record Official record
Conditions
Liver Cirrhosis, Renal Failure
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting No phase listed Observational

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

NCT06306963
View directory record Official record
Conditions
Gastric Antral Vascular Ectasia, Cirrhosis, Chronic Kidney Disease
Interventions
Gastric Emptying Breath Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 3 Interventional

A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.

NCT00275652
View directory record Official record
Conditions
Hepatitis B, Cirrhosis
Interventions
LdT (Telbivudine) and lamivudine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Timeline
2004 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis

NCT07035158
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Libra Oral Solution
Diagnostic Test
Lead sponsor
Owlstone Ltd
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Phase 2 Interventional

Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy

NCT04155099
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
RBX7455, Placebo
Biological
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Jefferson, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis

NCT04604652
View directory record Official record
Conditions
Primary Biliary Cholangitis, Primary Biliary Cirrhosis, Cholangitis, Cholestasis, Biliary Tract Diseases, Bile Duct Stricture
Interventions
HTD1801 (BUDCA)
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Miami, Florida • Atlanta, Georgia • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Recruiting Not applicable Interventional

Hospital @ Home Model of Care for Cirrhosis

NCT06396897
View directory record Official record
Conditions
Decompensated Cirrhosis
Interventions
Indiana University Health Hospital at Home Program
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

NCT06247735
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
K-808 (Dose A), K-808 (Dose B), Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
21
States / cities
Tucson, Arizona • Coronado, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 1 Interventional Results available

An Open-Label Study Following Oral Dosing of Seladelpar to Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

NCT04950764
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Interventions
Seladelpar
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
11
States / cities
Chandler, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Terminated Not applicable Interventional

Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis

NCT01951209
View directory record Official record
Conditions
Liver Cirrhosis, Chronic Hepatitis C
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
David E. Kaplan, MD MSc
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Oct 2, 2026, 4:11 AM EDT
Completed No phase listed Observational

A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)

NCT07049887
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
Not listed
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Chandler, Arizona • Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Low-Dose Danazol for the Treatment of Telomere Related Diseases

NCT03312400
View directory record Official record
Conditions
Telomere Disease
Interventions
Danazol
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Not yet recruiting Not applicable Interventional

Isocaloric Navy-Bean Substitution in Adults With MASLD

NCT07730853
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions
Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 2, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 2, 2026, 4:11 AM EDT